PARP Inhibitors Will “Remain Relevant” for mCRPC

Phase III findings from TRITON3 and TALAPRO-2 bear out the efficacy of PARP inhibitors in men with metastatic castration-resistant prostate cancer, particularly those harboring BRCA1/2 alterations. Compared with standard care, rucaparib—and separately, the addition of talazoparib to enzalutamide—extended radiographic progression-free survival with manageable side effects.